Overview

The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin

Status:
Completed
Trial end date:
2002-07-01
Target enrollment:
Participant gender:
Summary
Multiple-dose, open-label, single-period study consisting of three consecutive phases
Phase:
Phase 1
Details
Lead Sponsor:
Bial - Portela C S.A.
Treatments:
Eslicarbazepine acetate
Warfarin